“Amongst the many MEK inhibitors that have been clinical trials, responses have been seen in BRAF wildtype melanoma repeatedly. However, the response rate is not as high in BRAF wildtype as BRAF mutant melanoma for the same drugs (MEK inhibitors). While this has been known for several years now, the difficulty is that the response rate is sufficiently low that it’s not clear how to consider developing MEK inhibitors for BRAF wildtype patients as an entire group. The evidence presented this year at ASCO with MEK162 suggested that most of the benefit with these drugs may be in patients with an NRAS mutation. Even focusing on them, the results are not as good as in BRAF mutant patients. Nonetheless, it’s a lead.” We always will take leads with this disease!